Polianta Ltd Invests $1.37 Million in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Polianta Ltd invested approximately $1.365 million in Regeneron Pharmaceuticals by acquiring 2,600 shares during the second quarter.
• The company reported impressive quarterly earnings of $12.89 EPS, exceeding expectations and generating $3.68 billion in revenue, indicating a year-over-year revenue increase of 3.6%.
• Regeneron Pharmaceuticals announced a quarterly dividend of $0.88 per share, resulting in an annualized dividend yield of 0.6% and a payout ratio of 8.87%.

Polianta Ltd bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,600 shares of the biopharmaceutical company's stock, valued at approximately $1,365,000.

Other institutional investors have also made changes to their positions in the company. Marietta Wealth Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 30.2% during the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after purchasing an additional 2,501 shares in the last quarter. Sepio Capital LP raised its holdings in Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock valued at $2,150,000 after acquiring an additional 842 shares in the last quarter. GAMMA Investing LLC raised its holdings in Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Regeneron Pharmaceuticals by 3.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after acquiring an additional 955 shares in the last quarter. Finally, KBC Group NV raised its holdings in Regeneron Pharmaceuticals by 9.4% in the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after acquiring an additional 12,793 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a report on Monday, August 4th. Jefferies Financial Group upped their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a report on Wednesday, August 27th. Rothschild & Co Redburn assumed coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a "buy" rating and a $890.00 price target on the stock. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Finally, Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded down $6.72 during trading on Friday, hitting $591.99. 2,177,965 shares of the company's stock traded hands, compared to its average volume of 914,839. The stock has a fifty day moving average price of $567.77 and a two-hundred day moving average price of $575.90. The stock has a market capitalization of $62.75 billion, a price-to-earnings ratio of 14.92, a price-to-earnings-growth ratio of 2.00 and a beta of 0.35. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,154.56.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $11.56 earnings per share. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.